217 related articles for article (PubMed ID: 37175742)
21. Dabrafenib therapy for advanced melanoma.
Trinh VA; Davis JE; Anderson JE; Kim KB
Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
[TBL] [Abstract][Full Text] [Related]
22. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.
Bokharaie H; Kolch W; Krstic A
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883549
[TBL] [Abstract][Full Text] [Related]
25. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
26. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
[TBL] [Abstract][Full Text] [Related]
27. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in
Hartman ML; Rozanski M; Osrodek M; Zalesna I; Czyz M
Lab Invest; 2017 Feb; 97(2):217-227. PubMed ID: 28067893
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
[TBL] [Abstract][Full Text] [Related]
31. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib in Chinese patients with BRAF
Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
[TBL] [Abstract][Full Text] [Related]
33. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
35. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract][Full Text] [Related]
37. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
38. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
39. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
